New oral anticoagulants: comparative pharmacology with vitamin K antagonists (Q38071973)

28 August 2017

1 reference

title

New oral anticoagulants: comparative pharmacology with vitamin K antagonists (English)

1 reference

28 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

1 reference

Francesco Scaglione

1

1 reference

28 August 2017

1 February 2013

1 reference

Clinical Pharmacokinetics

28 August 2017

1 reference

28 August 2017

52

1 reference

28 August 2017

2

1 reference

28 August 2017

69-82

1 reference

https://scigraph.springernature.com/pub.10.1007/s40262-012-0030-9

28 August 2017

0 references

cites work

Estimation of the antihaemorrhagic vitamin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

The occurrence and chemical nature of vitamin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

The discovery of dicumarol and its sequels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Pharmacogenetics of oral anticoagulants: a basis for dose individualization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Medicine: K is for koagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Anticoagulant activity of the enantiomers of acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Clinically important drug interactions with anticoagulants. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Interaction of warfarin with drugs, natural substances, and foods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Factors influencing warfarin dose requirements in African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Guidelines on oral anticoagulation with warfarin - fourth edition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Why do patients with atrial fibrillation not receive warfarin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

New anticoagulants for treatment of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Apixaban metabolism and pharmacokinetics after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

The role of apixaban for venous and arterial thromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Dabigatran etexilate: a new oral thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Targeting thrombin – rational drug design from natural mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Hirudin as alternative anticoagulant--a historical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

New oral antithrombotics: a need for laboratory monitoring. Against

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

New oral anticoagulants in development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Structure-based design of novel potent nonpeptide thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-012-0030-9

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden

21 January 2018

1 reference

12 December 2020

Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis

1 reference

12 December 2020

Determination of the plasma protein binding of the coumarin anticoagulants phenprocoumon and its metabolites, warfarin and acenocoumarol, by ultrafiltration and high-performance liquid chromatography

1 reference

12 December 2020

Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention

1 reference

12 December 2020

Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats

1 reference

12 December 2020

Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects

1 reference

12 December 2020

Newly identified events in the RE-LY trial

1 reference

12 December 2020

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

1 reference

12 December 2020

Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.

1 reference

12 December 2020

In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban

1 reference

12 December 2020

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

1 reference

12 December 2020

The coagulation defect of vitamin K deficiency compared with that caused by dicumarol

1 reference

12 December 2020

Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats

1 reference

12 December 2020

In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate

1 reference

12 December 2020

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

1 reference

12 December 2020

The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats.

1 reference

12 December 2020

Studies on the mode of action of vitamin K

1 reference

12 December 2020

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

1 reference

12 December 2020

The enantiomers of phenprocoumon: pharmacodynamic and pharmacokinetic studies

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S40262-012-0030-9

Identifiers

DOI

1 reference

PubMed ID

23292752

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23292752